p69

ASP6918 是一种高效的口服KRAS G12C抑制剂，其IC50为0.028 µM。ASP6918 能抑制细胞生长，并展示出抗肿瘤活性。

Tofacitinib (Tasocitinib) 是一种 Janus 激酶抑制剂，抑制 JAK3/2/1 (IC50=1/20/112 nM)，具有口服活性。Tofacitinib 被用于治疗中度至重度类风湿性关节炎。

Tofacitinib Citrate (CP-690550 citrate) 是 JAK1/2/3抑制剂，IC50分别为112，20 和 1 nM。它具有抗菌，抗真菌和抗病毒活性。

DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

DuP-697 是一种不可逆的特异性 COX-2 抑制剂，对人 COX-2 和 COX-1 的 IC50 值为 10 nM 和 800 nM。 DuP-697 还具有抗血管生成、抗炎、解热和凋亡作用。

BMS-639623 is a CCR3 antagonist with a picomolar inhibitory effect on eosinophilic chemotaxis and can be used in the treatment of asthma.

CP 69799 is an inhibitor of aspartate proteinases.

Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.

RP-69758 is a bioactive chemical.

Quoromycin is a novel antivirulence agent against Vibrio vulnificus, inhibiting the quorum-sensing signaling pathway by controlling the DNA-binding affinity of SmcR and thus effectively alleviating the virulence of V. vulnificus in vitro and in vivo.

BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.

Gemfibrozil-d6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

DSP-6952 is a 5-HT4 receptor partial agonist, inhibiting visceral hypersensitivity and ameliorating gastrointestinal dysfunction.